Gilead Sciences (GILD) on Monday reported positive topline results from the Phase 3 ARTISTRY-2 trial.
This trial looked at switching from BIKTARVY to a new fixed-dose combo of bictegravir and lenacapavir for adults with HIV who are already virologically suppressed.
The once-a-day pill showed it performed just as well as BIKTARVY by Week 48, with similar levels of viral suppression and no new safety issues popping up. Gilead is planning to combine the findings from ARTISTRY-2 with those from ARTISTRY-1 to help with regulatory submissions and future scientific talks.
GILD is currently trading at $121.70 up $2.09 or 1.75 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.